VYNE shares surge 78.07% premarket after merger with Yarrow Bioscience, backed by $200M funding and YB-101 drug development.

VYNE Therapeutics Inc. surged 78.07% in premarket trading following the announcement of a definitive merger agreement with Yarrow Bioscience, a clinical-stage biotech focused on autoimmune thyroid diseases. The all-stock transaction, backed by $200 million in pre-closing financings led by RTW Investments and other healthcare investors, will create a combined company trading as YARW. The merger includes a $14.5–$16.5 million cash dividend to VYNE shareholders and accelerates the development of YB-101, a first-in-class anti-TSHR antibody for Graves’ disease and thyroid eye disease. The deal, expected to close in Q2 2026, positions the combined entity to advance YB-101 into U.S. trials in 2026, with data anticipated by late 2027. The merger’s strategic value, capital infusion, and dividend payout align with the stock’s sharp premarket increase, driven by optimism over the combined company’s pipeline and financial backing.